Last updated: 11/07/2018 00:52:49
An Open Label, Multicenter, Randomized, Phase II Study of Topotecan and Paclitaxel vs. Etoposide/Cisplatin as First Line Treatment in Patients with Extensive Disease Small Cell Lung Cancer
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: An Open Label, Multicenter, Randomized, Phase II Study of Topotecan and Paclitaxel vs. Etoposide/Cisplatin as First Line Treatment in Patients with Extensive Disease Small Cell Lung Cancer
Trial description: An Open Label, Multicenter, Randomized, Phase II Study of Topotecan and Paclitaxel vs. Etoposide/Cisplatin as First Line Treatment in Patients with Extensive Disease Small Cell Lung Cancer
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Lena H et.al. Randomized, phase II study of topotecan/paclitaxel versus cisplatin/etoposide in patients with untreated, extensive disease, small cell lung cancer (SCLC), ECCO (European Conference of Clinical Oncology 2001): abstract 217, s62
Lena H, Breton JL, Yu W, Steppert K, Lightcap K, Ross G, Lymboura M. Randomized, phase II study of topotecan/paclitaxel vs cisplatin/etoposide in patients with untreated, extensive disease, small cell lung cancer (SCLC). Eur J Cancer. 2001;37(suppl6):S62.
Phase 11 study: first line treatment of stage iv small.coll lung cancer with topotecan and paclitaxel. W. Schatte, 1 Bork K. A hlmann T. Blanken burg B. Wollschlager S. Ka-u-b-it-zs-ch and 37th Annual Meeting of the American Society of Clinical Oncology 5/12/2001 San Francisco, CA; USA
Randomized, phase 11 study otlopotecan/paelltaxel versus cisplatinietoposide in patients with untreated, extensive disease, small cell lung cancer (sclc). H. Lena, J. Breton W. Yu K. Steppert K. Lightcap G. Ross M. Lymbouras. ECCO : 11th European Conference on Clinical Oncology and Cancer Nursing - Together with the European Association for Cancer Research (EACR), European Oncology Nursing Society (EONS), European Society for Medical Oncology (ESMO), European Society of Surg 10/21/2001 Lisbon; Portugal"
Medical condition
Lung Cancer, Small Cell
Product
topotecan
Collaborators
Not applicable
Study date(s)
March 1999 to June 2001
Type
Not applicable
Phase
2
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2001-29-06
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website